Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Asset Writedowns and Impairment: 2022-2024

Historic Asset Writedowns and Impairment for OptimizeRx (OPRX) over the last 3 years, with Q4 2024 value amounting to $7.4 million.

  • OptimizeRx's Asset Writedowns and Impairment rose 1753.99% to $7.4 million in Q4 2024 from the same period last year, while for Jun 2025 it was $7.4 million, marking a year-over-year increase of 1278.36%. This contributed to the annual value of $7.5 million for FY2024, which is 1114.57% up from last year.
  • As of Q4 2024, OptimizeRx's Asset Writedowns and Impairment stood at $7.4 million, which was up 1753.99% from -$1000.0 recorded in Q3 2024.
  • In the past 5 years, OptimizeRx's Asset Writedowns and Impairment registered a high of $7.4 million during Q4 2024, and its lowest value of -$1000.0 during Q3 2024.
  • Its 3-year average for Asset Writedowns and Impairment is $1.3 million, with a median of $128000.0 in 2023.
  • In the last 5 years, OptimizeRx's Asset Writedowns and Impairment skyrocketed by 261248.13% in 2023 and then plummeted by 10041.84% in 2024.
  • OptimizeRx's Asset Writedowns and Impairment (Quarter) stood at $230785.0 in 2022, then soared by 2612.48% to $6.3 million in 2023, then grew by 17.54% to $7.4 million in 2024.
  • Its Asset Writedowns and Impairment stands at $7.4 million for Q4 2024, versus -$1000.0 for Q3 2024 and $132000.0 for Q1 2024.